Zentalis Pharmaceuticals, Inc. (ZNTL) Current Ratio
- Current ratio · latest quarter: Value 4.82×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.82× | Current assets / current liabilities. $181.28M ÷ $37.63M ≈ 4.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 181.28M USD | Assets, Current |
| Current obligations | 37.63M USD | Liabilities, Current |
| Cash and equivalents | 24.78M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 149.82M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 8.14M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $181.28M | $37.63M | $24.78M | $149.82M | (m) | (m) | $8.14M | (m) | 4.82× |
| 2026-03-31 | $218.10M | $35.24M | $31.93M | $179.83M | (m) | (m) | $7.38M | (m) | 6.19× |
| 2025-12-31 | $253.19M | $36.56M | $35.99M | $209.90M | (m) | (m) | $7.21M | (m) | 6.93× |
| 2025-09-30 | $288.30M | $37.17M | $39.07M | $239.22M | $0.00 | (m) | $7.03M | (m) | 7.76× |
| 2025-06-30 | $311.60M | $39.02M | $37.60M | $249.04M | $0.00 | (m) | $3.72M | (m) | 7.99× |
| 2025-03-31 | $342.88M | $49.43M | $41.93M | $278.37M | $0.00 | (m) | $7.77M | (m) | 6.94× |
| 2024-12-31 | $386.07M | $52.73M | $33.90M | $318.01M | $5.00M | (m) | $7.44M | (m) | 7.32× |
| 2024-09-30 | $400.27M | $54.88M | $41.32M | (m) | (m) | (m) | $8.20M | (m) | 7.29× |
| 2024-06-30 | $439.62M | $66.69M | $36.98M | (m) | (m) | (m) | $20.44M | (m) | 6.59× |
| 2024-03-31 | $503.81M | $54.80M | $37.62M | (m) | (m) | (m) | $10.50M | (m) | 9.19× |
| 2023-12-31 | $496.72M | $69.37M | $28.04M | $454.88M | $0.00 | (m) | $14.93M | (m) | 7.16× |
| 2023-09-30 | $528.26M | $58.92M | $110.75M | (m) | (m) | (m) | $14.26M | (m) | 8.97× |
| 2023-06-30 | $563.93M | $51.76M | $266.56M | (m) | (m) | (m) | $12.30M | (m) | 10.90× |
| 2023-03-31 | $410.23M | $56.36M | $36.28M | (m) | (m) | (m) | $12.82M | (m) | 7.28× |
| 2022-12-31 | $451.93M | $56.65M | $43.07M | (m) | (m) | (m) | $11.25M | (m) | 7.98× |
| 2022-09-30 | $433.89M | $54.06M | $42.55M | (m) | (m) | (m) | $9.82M | (m) | 8.03× |
| 2022-06-30 | $467.63M | $48.64M | $55.14M | (m) | (m) | (m) | $12.04M | (m) | 9.61× |
| 2022-03-31 | $301.28M | $43.48M | $30.57M | (m) | (m) | (m) | $13.16M | (m) | 6.93× |
| 2021-12-31 | $350.77M | $43.94M | $59.71M | (m) | (m) | (m) | $11.59M | (m) | 7.98× |
| 2021-09-30 | $377.56M | $39.41M | $40.81M | (m) | $108.00K | (m) | $8.05M | (m) | 9.58× |
| 2021-06-30 | $259.45M | $33.58M | $49.17M | (m) | $5.00K | (m) | $8.27M | (m) | 7.73× |
| 2021-03-31 | $306.35M | $32.80M | $29.00M | $269.38M | $248.00K | (m) | $8.34M | (m) | 9.34× |
| 2020-12-31 | $345.10M | $28.60M | $54.95M | (m) | $417.00K | (m) | $8.66M | (m) | 12.07× |
| 2020-09-30 | $372.74M | $23.91M | $92.55M | (m) | $122.00K | (m) | $5.44M | (m) | 15.59× |
| 2020-06-30 | $238.48M | $15.57M | $96.02M | (m) | $73.00K | (m) | $4.22M | (m) | 15.32× |
| 2020-03-31 | $66.01M | $16.94M | $63.65M | (m) | $139.00K | (m) | $7.02M | (m) | 3.90× |
| 2019-12-31 | $68.89M | $14.90M | $67.25M | (m) | $140.00K | (m) | $4.29M | (m) | 4.62× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |